Preventing Anthracycline-Induced Cardiotoxicity Using Functional Genomics and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Circulation. 2022 Jan 25;145(4):295-298. doi: 10.1161/CIRCULATIONAHA.121.058128. Epub 2022 Jan 24.

Authors

Valentina Lo Sardo^{1

2}, Timothy J Kamp^{1

2

3}

Affiliations

¹ Department of Cell and Regenerative Biology (V.LS., T.J.K.), University of Wisconsin-Madison.
² Stem Cell and Regenerative Medicine Center (V.LS., T.J.K.), University of Wisconsin-Madison.
³ Department of Medicine (T.J.K.), University of Wisconsin-Madison.

PMID: 35073175
DOI: 10.1161/CIRCULATIONAHA.121.058128

No abstract available

Keywords: Editorials; anthracyclines; doxorubicin; genetic loci; induced pluripotent stem cells; myocytes, cardiac.

Publication types

Editorial
Comment

MeSH terms

Anthracyclines / toxicity
Antibiotics, Antineoplastic / toxicity
Cardiotoxicity* / genetics
Cardiotoxicity* / prevention & control
Doxorubicin / toxicity
Genomics
Humans
Induced Pluripotent Stem Cells* / drug effects
Myocytes, Cardiac / drug effects

Substances

Anthracyclines
Antibiotics, Antineoplastic
Doxorubicin